Abstract
The L858R mutation in EGFR is particularly responsive to small tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. This efficacy decrea......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
